Genome-wide analysis of DHEA- and DHT-induced gene expression in mouse hypothalamus and hippocampus

Journal of Steroid Biochemistry and Molecular Biology

Volumn 114, Issue 3-5, 2009, Pages 135-143

  Mo, Qianxing ^a   Lu, Shifang ^a   Garippa, Carrie ^a   Brownstein, Michael J ^b   Simon, Neal G ^a  

^a LEHIGH UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Androgen receptor; CNS; Dehydroepiandrosterone (DHEA); Genomics; Mechanism of action

Indexed keywords

ANDROGEN; ANDROSTANOLONE; CHITINASE; CHITINASE 3 LIKE 3; ESTRADIOL; MELANIN CONCENTRATING HORMONE; OREXIN; PRASTERONE; PRO MELANIN CONCENTRATING HORMONE; PROTEIN DBCCR1; PROTEIN KINASE C DELTA; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; FEMALE; GENE CONTROL; GENE EXPRESSION; GENOME ANALYSIS; HIPPOCAMPUS; HYPOTHALAMUS; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARIECTOMY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; APOPTOSIS; APPETITE; CELL SURVIVAL; DEHYDROEPIANDROSTERONE; DIHYDROTESTOSTERONE; ENERGY METABOLISM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENOME; HIPPOCAMPUS; HYPOTHALAMUS; MICE; MICE, INBRED STRAINS; RECEPTORS, ANDROGEN;

MUS;

EID: 63049120688     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2009.01.015     Document Type: Article

References (85)

1. Arlt W. Dehydroepiandrosterone and ageing. Best Pract. Res. Clin. Endocrinol. Metab. 18 3 (2004) 363-380
2. Baulieu E.E., and Robel P. Dehydroepiandrosterone and dehydroepiandrosterone sulfate as neuroactive neurosteroids. J. Endocrinol. 150 Suppl. (1996) S221-239
3. Compagnone N.A., and Mellon S.H. Neurosteroids: biosynthesis and function of these novel neuromodulators. Front. Neuroendocrinol. 21 1 (2000) 1-56
4. Allolio B., Arlt W., and Hahner S. DHEA: why, when, and how much-DHEA replacement in adrenal insufficiency. Ann. Endocrinol. (Paris) 68 4 (2007) 268-273
5. Eser D., Schule C., Baghai T.C., Romeo E., Uzunov D.P., and Rupprecht R. Neuroactive steroids and affective disorders. Pharmacol. Biochem. Behav. 84 4 (2006) 656-666
6. Hunt P.J., Gurnell E.M., Huppert F.A., Richards C., Prevost A.T., Wass J.A., Herbert J., and Chatterjee V.K. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. J. Clin. Endocrinol. Metab. 85 12 (2000) 4650-4656
7. Malkesman O., Braw Y., Ram E., Maayan R., Weizman A., Kinor N., Yadid G., and Weller A. Dehydroepiandrosterone and monoamines in the limbic system of a genetic animal model of childhood depression. Eur Neuropsychopharmacol 18 4 (2008) 255-261
8. Panjari M., and Davis S.R. DHEA therapy for women: effect on sexual function and wellbeing. Hum. Reprod. Update 13 3 (2007) 239-248
9. Maninger N., Wolkowitz O.M., Reus V.I., Epel E.S., and Mellon S.H. Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). Front Neuroendocrinol 30 1 (2009) 65-91
10. Chen L., Miyamoto Y., Furuya K., Dai X.N., Mori N., and Sokabe M. Chronic DHEAS administration facilitates hippocampal long-term potentiation via an amplification of Src-dependent NMDA receptor signaling. Neuropharmacology 51 3 (2006) 659-670
11. Kimonides V.G., Khatibi N.H., Svendsen C.N., Sofroniew M.V., and Herbert J. Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEAS) protect hippocampal neurons against excitatory amino acid-induced neurotoxicity. Proc. Natl. Acad. Sci. U.S.A. 95 4 (1998) 1852-1857
12. Lapchak P.A., and Araujo D.M. Preclinical development of neurosteroids as neuroprotective agents for the treatment of neurodegenerative diseases. Int. Rev. Neurobiol. 46 (2001) 379-397
13. Parducz A., Hajszan T., Maclusky N.J., Hoyk Z., Csakvari E., Kurunczi A., Prange-Kiel J., and Leranth C. Synaptic remodeling induced by gonadal hormones: neuronal plasticity as a mediator of neuroendocrine and behavioral responses to steroids. Neuroscience 138 3 (2006) 977-985
14. Vallee M., Mayo W., and Le Moal M. Role of pregnenolone, dehydroepiandrosterone and their sulfate esters on learning and memory in cognitive aging. Brain Res. Brain Res. Rev. 37 1-3 (2001) 301-312
15. Genazzani A.D., Lanzoni C., and Genazzani A.R. Might DHEA be considered a beneficial replacement therapy in the elderly?. Drugs Aging 24 3 (2007) 173-185
16. Achermann J.C., and Silverman B.L. Dehydroepiandrosterone replacement for patients with adrenal insufficiency. Lancet 357 9266 (2001) 1381-1382
17. Labrie F., Luu-The V., Belanger A., Lin S.X., Simard J., Pelletier G., and Labrie C. Is dehydroepiandrosterone a hormone?. J. Endocrinol. 187 2 (2005) 169-196
18. Komesaroff P.A. Unravelling the enigma of dehydroepiandrosterone: moving forward step by step. Endocrinology 149 3 (2008) 886-888
19. von Muhlen D., Laughlin G.A., Kritz-Silverstein D., and Barrett-Connor E. The Dehydroepiandrosterone And WellNess (DAWN) study: research design and methods. Contemp. Clin. Trials 28 2 (2007) 153-168
20. Mehta A.K., and Ticku M.K. An update on GABAA receptors. Brain Res. Brain Res. Rev. 29 2-3 (1999) 196-217
21. Bergeron R., de Montigny C., and Debonnel G. Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors. J. Neurosci. 16 3 (1996) 1193-1202
22. Demirgoren S., Majewska M.D., Spivak C.E., and London E.D. Receptor binding and electrophysiological effects of dehydroepiandrosterone sulfate, an antagonist of the GABAA receptor. Neuroscience 45 1 (1991) 127-135
23. Monnet F.P., Mahe V., Robel P., and Baulieu E.E. Neurosteroids, via sigma receptors, modulate the [3H]norepinephrine release evoked by N-methyl-d-aspartate in the rat hippocampus. Proc. Natl. Acad. Sci. U.S.A. 92 9 (1995) 3774-3778
24. Lu S.F., Mo Q., Hu S., Garippa C., and Simon N.G. Dehydroepiandrosterone upregulates neural androgen receptor level and transcriptional activity. J. Neurobiol. 57 2 (2003) 163-171
25. Mo Q., Lu S.F., Hu S., and Simon N.G. DHEA and DHEA sulfate differentially regulate neural androgen receptor and its transcriptional activity. Brain Res. Mol. Brain Res. 126 2 (2004) 165-172
26. Mo Q., Lu S.F., and Simon N.G. Dehydroepiandrosterone and its metabolites: differential effects on androgen receptor trafficking and transcriptional activity. J. Steroid Biochem. Mol. Biol. 99 1 (2006) 50-58
27. Lu S.F., McKenna S.E., Cologer-Clifford A., Nau E.A., and Simon N.G. Androgen receptor in mouse brain: sex differences and similarities in autoregulation. Endocrinology 139 4 (1998) 1594-1601
28. Lu S., Simon N.G., Wang Y., and Hu S. Neural androgen receptor regulation: effects of androgen and antiandrogen. J. Neurobiol. 41 4 (1999) 505-512
29. Xiao L., and Jordan C.L. Sex differences, laterality, and hormonal regulation of androgen receptor immunoreactivity in rat hippocampus. Horm. Behav. 42 3 (2002) 327-336
30. Smyth G.K., and Speed T. Normalization of cDNA microarray data. Methods 31 4 (2003) 265-273
31. P.H. Westfall, S.S. Yong, Resampling-based multiple testing: examples and methods for p-value adjustment, John Wiley & Sons, New York, 1993.
32. Benjamini Y., and Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. Roy. Statist. Soc. B: Methodol. 57 1 (1995) 289-300
33. Eisen M.B., Spellman P.T., Brown P.O., and Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U.S.A. 95 25 (1998) 14863-14868
34. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 4 (2001) 402-408
35. Franklin Keith B.J., and Paxinos G. The Mouse Brain in Stereotaxic Coordinates (1997), Academic Press
36. Bittencourt J.C., Presse F., Arias C., Peto C., Vaughan J., Nahon J.L., Vale W., and Sawchenko P.E. The melanin-concentrating hormone system of the rat brain: an immuno- and hybridization histochemical characterization. J. Comp. Neurol. 319 2 (1992) 218-245
37. Peyron C., Tighe D.K., van den Pol A.N., de Lecea L., Heller H.C., Sutcliffe J.G., and Kilduff T.S. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 18 23 (1998) 9996-10015
38. Arora S., and Anubhuti. Role of neuropeptides in appetite regulation and obesity-a review. Neuropeptides 40 6 (2006) 375-401
39. Nahon J.L. The melanocortins and melanin-concentrating hormone in the central regulation of feeding behavior and energy homeostasis. Comptes Rendus Biol. 329 8 (2006) 623-638 (discussion 653-625)
40. Pissios P., Bradley R.L., and Maratos-Flier E. Expanding the scales: the multiple roles of MCH in regulating energy balance and other biological functions. Endocr. Rev. 27 6 (2006) 606-620
41. Nishino S. Clinical and neurobiological aspects of narcolepsy. Sleep Med. 8 4 (2007) 373-399
42. Sakurai T. Roles of orexins and orexin receptors in central regulation of feeding behavior and energy homeostasis. CNS Neurol. Disord. Drug Targets 5 3 (2006) 313-325
43. Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat. Rev. Neurosci. 8 3 (2007) 171-181
44. Zeitzer J.M., Nishino S., and Mignot E. The neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions. Trends Pharmacol. Sci. 27 7 (2006) 368-374
45. Allolio B., and Arlt W. DHEA treatment: myth or reality?. Trends Endocrinol. Metab. 13 (2002) 288-294
46. Hucklebridge F., Hussain T., Evans P., and Clow A. The diurnal patterns of the adrenal steroids cortisol and dehydroepiandrosterone (DHEA) in relation to awakening. Psychoneuroendocrinology 30 1 (2005) 51-57
47. Johannsson G., Burman P., Wiren L., Engstrom B.E., Nilsson A.G., Ottosson M., Jonsson B., Bengtsson B.A., and Karlsson F.A. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J. Clin. Endocrinol. Metab. 87 5 (2002) 2046-2052
48. Guay A., Jacobson J., Munarriz R., Traish A., Talakoub L., Quirk F., Goldstein I., and Spark R. Serum androgen levels in healthy premenopausal women with and without sexual dysfunction. Part B. Reduced serum androgen levels in healthy premenopausal women with complaints of sexual dysfunction. Int. J. Impot. Res. 16 2 (2004) 121-129
49. Hahner S., and Allolio B. Management of adrenal insufficiency in different clinical settings. Expert Opin. Pharmacother. 6 14 (2005) 2407-2417
50. Rabkin J.G., McElhiney M.C., Rabkin R., McGrath P.J., and Ferrando S.J. Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS. Am. J. Psychiatry 163 1 (2006) 59-66
51. Schmidt P.J., Daly R.C., Bloch M., Smith M.J., Danaceau M.A., St Clair L.S., Murphy J.H., Haq N., and Rubinow D.R. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch. Gen. Psychiatry 62 2 (2005) 154-162
52. David D.J., Klemenhagen K.C., Holick K.A., Saxe M.D., Mendez I., Santarelli L., Craig D.A., Zhong H., Swanson C.J., Hegde L.G., Ping X.I., Dong D., Marzabadi M.R., Gerald C.P., and Hen R. Efficacy of the MCHR1 antagonist N-[3-(1-{[4-(3,4-difluorophenoxy)phenyl]methyl}(4-piperidyl))-4-methylphen yl]-2-methylpropanamide (SNAP 94847) in mouse models of anxiety and depression following acute and chronic administration is independent of hippocampal neurogenesis. J. Pharmacol. Exp. Ther. 321 1 (2007) 237-248
53. Shimazaki T., Yoshimizu T., and Chaki S. Melanin-concentrating hormone MCH1 receptor antagonists: a potential new approach to the treatment of depression and anxiety disorders. CNS Drugs 20 10 (2006) 801-811
54. Basso A.M., Bratcher N.A., Gallagher K.B., Cowart M.D., Zhao C., Sun M., Esbenshade T.A., Brune M.E., Fox G.B., Schmidt M., Collins C.A., Souers A.J., Iyengar R., Vasudevan A., Kym P.R., Hancock A.A., and Rueter L.E. Lack of efficacy of melanin-concentrating hormone-1 receptor antagonists in models of depression and anxiety. Eur. J. Pharmacol. 540 1-3 (2006) 115-120
55. Gonzalez M.I., Vaziri S., and Wilson C.A. Behavioral effects of alpha-MSH and MCH after central administration in the female rat. Peptides 17 1 (1996) 171-177
56. Morens C., Norregaard P., Receveur J.M., van Dijk G., and Scheurink A.J. Effects of MCH and a MCH1-receptor antagonist on (palatable) food and water intake. Brain Res. 1062 1-2 (2005) 32-38
57. Whitlock B.K., Daniel J.A., McMahon C.D., Buonomo F.C., Wagner C.G., Steele B., and Sartin J.L. Intracerebroventricular melanin-concentrating hormone stimulates food intake in sheep. Domest. Anim. Endocrinol. 28 2 (2005) 224-232
58. J.W. Muschamp, S. Sato, E.M. Hull, Castration decreases hypocretin/orexin immunoreactivity in hypothalamus of male rats, Soc. Neurosci. Abst. 320.10 (2005).
59. Cerda-Reverter J.M., Canosa L.F., and Peter R.E. Regulation of the hypothalamic melanin-concentrating hormone neurons by sex steroids in the goldfish: possible role in the modulation of luteinizing hormone secretion. Neuroendocrinology 84 6 (2006) 364-377
60. Koponen S., Goldsteins G., Keinanen R., and Koistinaho J. Induction of protein kinase Cdelta subspecies in neurons and microglia after transient global brain ischemia. J. Cereb. Blood Flow Metab. 20 1 (2000) 93-102
61. Miettinen S., Roivainen R., Keinanen R., Hokfelt T., and Koistinaho J. Specific induction of protein kinase C delta subspecies after transient middle cerebral artery occlusion in the rat brain: inhibition by MK-801. J. Neurosci. 16 19 (1996) 6236-6245
62. Jane E.P., Premkumar D.R., and Pollack I.F. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. J. Pharmacol. Exp. Ther. 319 3 (2006) 1070-1080
63. Choi B.H., Hur E.M., Lee J.H., Jun D.J., and Kim K.T. Protein kinase Cdelta-mediated proteasomal degradation of MAP kinase phosphatase-1 contributes to glutamate-induced neuronal cell death. J. Cell Sci. 119 Pt 7 (2006) 1329-1340
64. Reyland M.E., Anderson S.M., Matassa A.A., Barzen K.A., and Quissell D.O. Protein kinase C delta is essential for etoposide-induced apoptosis in salivary gland acinar cells. J. Biol. Chem. 274 27 (1999) 19115-19123
65. Habuchi T., Luscombe M., Elder P.A., and Knowles M.A. Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. Genomics 48 3 (1998) 277-288
66. Nishiyama H., Gill J.H., Pitt E., Kennedy W., and Knowles M.A. Negative regulation of G(1)/S transition by the candidate bladder tumour suppressor gene DBCCR1. Oncogene 20 23 (2001) 2956-2964
67. Wright K.O., Messing E.M., and Reeder J.E. DBCCR1 mediates death in cultured bladder tumor cells. Oncogene 23 1 (2004) 82-90
68. Giannetti N., Moyse E., Ducray A., Bondier J.R., Jourdan F., Propper A., and Kastner A. Accumulation of Ym1/2 protein in the mouse olfactory epithelium during regeneration and aging. Neuroscience 123 4 (2004) 907-917
69. DeVries-Seimon T.A., Ohm A.M., Humphries M.J., and Reyland M.E. Induction of apoptosis is driven by nuclear retention of protein kinase C delta. J. Biol. Chem. 282 31 (2007) 22307-22314
70. Grossoni V.C., Falbo K.B., Kazanietz M.G., de Kier Joffe E.D., and Urtreger A.J. Protein kinase C delta enhances proliferation and survival of murine mammary cells. Mol. Carcinog. 46 5 (2007) 381-390
71. Beetz C., Brodoehl S., Patt S., Kalff R., and Deufel T. Low expression but infrequent genomic loss of the putative tumour suppressor DBCCR1 in astrocytoma. Oncol. Rep. 13 2 (2005) 335-340
72. Charalampopoulos I., Alexaki V.I., Tsatsanis C., Minas V., Dermitzaki E., Lasaridis I., Vardouli L., Stournaras C., Margioris A.N., Castanas E., and Gravanis A. Neurosteroids as endogenous inhibitors of neuronal cell apoptosis in aging. Ann. N.Y. Acad. Sci. 1088 (2006) 139-152
73. Hammond J., Le Q., Goodyer C., Gelfand M., Trifiro M., and LeBlanc A. Testosterone-mediated neuroprotection through the androgen receptor in human primary neurons. J. Neurochem. 77 5 (2001) 1319-1326
74. Aragno M., Parola S., Brignardello E., Mauro A., Tamagno E., Manti R., Danni O., and Boccuzzi G. Dehydroepiandrosterone prevents oxidative injury induced by transient ischemia/reperfusion in the brain of diabetic rats. Diabetes 49 11 (2000) 1924-1931
75. Li H., Klein G., Sun P., and Buchan A.M. Dehydroepiandrosterone (DHEA) reduces neuronal injury in a rat model of global cerebral ischemia. Brain Res. 888 2 (2001) 263-266
76. Ahlbom E., Prins G.S., and Ceccatelli S. Testosterone protects cerebellar granule cells from oxidative stress-induced cell death through a receptor mediated mechanism. Brain Res. 892 (2001) 255-262
77. Labrie F., Cusan L., Gomez J.L., Martel C., Berube R., Belanger P., Chaussade V., Deloche C., and Leclaire J. Changes in serum DHEA and eleven of its metabolites during 12-month percutaneous administration of DHEA. J. Steroid Biochem. Mol. Biol. (2008)
78. Cui H., Lin S.Y., and Belsham D.D. Evidence that dehydroepiandrosterone, DHEA, directly inhibits GnRH gene expression in GT1-7 hypothalamic neurons. Mol. Cell. Endocrinol. 203 1-2 (2003) 13-23
79. Morfin R., and Starka L. Neurosteroid 7-hydroxylation products in the brain. Int. Rev. Neurobiol. 46 (2001) 79-95
80. Jellinck P.H., Croft G., McEwen B.S., Gottfried-Blackmore A., Jones G., Byford V., and Bulloch K. Metabolism of dehydroepiandrosterone by rodent brain cell lines: relationship between 7-hydroxylation and aromatization. J. Steroid Biochem. Mol. Biol. 93 1 (2005) 81-86
81. Jellinck P.H., Kaufmann M., Gottfried-Blackmore A., McEwen B.S., Jones G., and Bulloch K. Selective conversion by microglia of dehydroepiandrosterone to 5-androstenediol-A steroid with inherent estrogenic properties. J. Steroid Biochem. Mol. Biol. 107 3-5 (2007) 156-162
82. Akwa Y., Sananes N., Gouezou M., Robel P., Baulieu E.E., and Le Goascogne C. Astrocytes and neurosteroids: metabolism of pregnenolone and dehydroepiandrosterone. Regulation by cell density. J. Cell Biol. 121 1 (1993) 135-143
83. Zwain I.H., and Yen S.S. Neurosteroidogenesis in astrocytes, oligodendrocytes, and neurons of cerebral cortex of rat brain. Endocrinology 140 8 (1999) 3843-3852
84. Labrie F., Luu-The V., Martel C., Chernomoretz A., Calvo E., Morissette J., and Labrie C. Dehydroepiandrosterone (DHEA) is an anabolic steroid like dihydrotestosterone (DHT), the most potent natural androgen, and tetrahydrogestrinone (THG). J. Steroid Biochem. Mol. Biol. 100 1-3 (2006) 52-58
85. Steele V.E., Arnold J.T., Lei H., Izmirlian G., and Blackman M.R. Comparative effects of DHEA and DHT on gene expression in human LNCaP prostate cancer cells. Anticancer Res. 26 5A (2006) 3205-3215